AbbVie
Products and tools
FDA Approves Subcutaneous Induction for AbbVie's Skyrizi in Crohn's Disease
The U.S. Food and Drug Administration has approved a subcutaneous induction regimen for AbbVie's Skyrizi (risankizumab-rzaa) in adults with moderately to severely active…
ResearchAbbVie Presents Long-Term Skyrizi and Rinvoq IBD Data at UEG Week 2026
AbbVie is presenting 20 new scientific abstracts from its inflammatory bowel disease portfolio at the 2026 United European Gastroenterology (UEG) Week in Barcelona…